SEMATHERA
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
SEMATHERA
Industry:
Biotechnology Diabetes Therapeutics
Founded:
2016-01-01
Address:
Westmount, Quebec, Canada
Country:
Canada
Website Url:
http://www.semathera.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Employees Featured
Founder
Investors List
Amorchem
Amorchem investment in Venture Round - Semathera
Senju Pharmaceutical
Senju Pharmaceutical investment in Venture Round - Semathera
Official Site Inspections
http://www.semathera.com Semrush global rank: 5.42 M Semrush visits lastest month: 1.56 K
- Host name: 238.168.203.35.bc.googleusercontent.com
- IP address: 35.203.168.238
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Semathera"
About Us - SemaThera Inc.
SemaThera was founded in Montreal, Quebec, where the company’s research and development facilities are located. In addition, it has operations in Boston, MA. 4 Westmount Square, Suite …See details»
Semathera - Crunchbase Company Profile & Funding
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology …See details»
SemaThera Company Profile | Management and Employees List
SemaThera Profile and History SemaThera (www.semathera.com) is a Montreal-based biotech company focusing on the development of novel therapies for the treatment of several …See details»
Overview - SemaThera Inc.
SemaThera develops novel semaphorin 3A (SEMA 3A) inhibitors for the prevention and reversal of diabetic macular edema (DME). SEMA 3A is a soluble protein that promotes vascular …See details»
SemaThera Inc: Contact Details and Business Profile
SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF …See details»
Semathera's CEO and Executive Team - Team members and org …
The executive team at Semathera has experience in a variety of industries, including pharmaceuticals, biomedical research, and genetics. They have education from some of the …See details»
SemaThera Inc - LinkedIn
SemaThera Inc | 326 followers on LinkedIn. SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is …See details»
Semathera's Leadership Team Team - Team members and org …
The Semathera leadership team has experience in a variety of industries, including pharmaceuticals, biomedical research, and genetics. They have also been educated at some …See details»
SemaThera Company Profile 2024: Valuation, Funding & Investors
SemaThera General Information Description. Operator of a biotechnology company intended to treat ocular diseases. The company develops novel anti-SEMA 3A therapies for the treatment …See details»
Semathera Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Semathera Inc of Westmount, QC. Get the latest business insights from Dun & Bradstreet.See details»
SemaThera Company Profile - Office Locations, Competitors
SemaThera has 5 employees at their 1 location and $1 m in total funding,. See insights on SemaThera including office locations, competitors, revenue, financials, executives, …See details»
SemaThera - Products, Competitors, Financials, Employees, …
SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche. Mar 22, 2021. March 22, 2021 08:00 AM Eastern Daylight Time MONTREAL--( BUSINESS …See details»
Semathera - VentureRadar
SemaThera develops novel inhibitors of semaphorin 3A (SEMA3A) for the prevention and reversal of retinal vascular diseases such as diabetic retinopathy (DR) and diabetic macular edema …See details»
SemaThera - Overview, News & Similar companies | ZoomInfo.com
Mar 22, 2021 SemaThera (www.semathera.com) is a Montreal-based biotech company focusing on the development of novel therapies for the treatment of several retin opathies, including …See details»
Management - SemaThera Inc.
Garth is the President & Chief Executive Officer of SemaThera. Additionally, he is chairman of the Board of Directors of Eyevensys, a French biotechnology company developing novel non-viral …See details»
Semathera - Contacts, Employees, Board Members, Advisors
Semathera has 3 current employee profiles, including Founder and Chief Scientific Officer Przemyslaw Sapieha. Przemyslaw Sapieha Founder and Chief Scientific Officer Garth …See details»
Partners - SemaThera Inc.
More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and …See details»
SemaThera Reviews: What Is It Like to Work At SemaThera?
Jun 12, 2024 1 SemaThera reviews. A free inside look at company reviews and salaries posted anonymously by employees.See details»
News - SemaThera Inc.
Aug 12, 2018 SemaThera (www.semathera.com) is a Montreal-based biotech company focused on the development of novel anti-SEMA3A therapies for the treatment of several retinopathies, …See details»